Clinical Trial: Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Brief Summary: Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Detailed Summary:
Sponsor: Benha University

Current Primary Outcome: Change in serum uric acid [ Time Frame: at three months of Febuxostat 40 milligrams Tablet therapy ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Benha University

Dates:
Date Received: May 10, 2017
Date Started: January 1, 2017
Date Completion:
Last Updated: May 10, 2017
Last Verified: May 2017